Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 8/20 | 0.36 |
| ▸ | NOS2 | P35228 | 8/20 | 0.36 |
| ▸ | NOS3 | P29474 | 3/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.34 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665788 | 0.98 | SCN2A (0.36) | NOS1NOS2NOS3SCN2AGBA1 | |
| SCHEMBL11138004 | 0.98 | SCN2A (0.36) | NOS1NOS2NOS3SCN2AGBA1 | |
| SCHEMBL20954129 | 0.98 | SCN2A (0.36) | NOS1NOS2NOS3SCN2AGBA1 | |
| SCHEMBL20954138 | 0.98 | SCN2A (0.36) | NOS1NOS2NOS3SCN2AGBA1 | |
| SCHEMBL7778391 | 0.91 | LMNA (0.39) | SCN2AGBA1 | |
| SCHEMBL10903471 | 0.89 | NOS1 (0.40) | NOS1NOS2NOS3 | |
| SCHEMBL9955184 | 0.89 | PSMD14 (0.34) | SCN2AGBA1 | |
| SCHEMBL8034064 | 0.89 | PSMD14 (0.34) | SCN2AGBA1 | |
| SCHEMBL2007679 | 0.89 | PSMD14 (0.34) | SCN2AGBA1 | |
| SCHEMBL5986996 | 0.89 | PSMD14 (0.34) | SCN2AGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087216-B1 | BIS-IMIDAZOLINE COMPOUNDS AS CORROSION INHIBITORS AND PREPARATION THEREOF | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20160319442-A1 | BIS-IMIDAZOLINE COMPOUNDS AS CORROSION INHIBITORS AND PREPARATION THEREOF | DOW INTERNATIONAL TECHNOLOGY CORPORATION | 2016-11-03 | — | — | US | disclosed |
| US-6380237-B1 | AS PESTICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-30 | — | — | US | disclosed |
| EP-1095023-A1 | DIPHENYLIMIDAZOLINES | BAYER AG (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000003995-A1 | DIPHENYLIMIDAZOLINES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160319442-A1 | BIS-IMIDAZOLINE COMPOUNDS AS CORROSION INHIBITORS AND PREPARATION THEREOF | SOD1, FHIT, TFPI | NOS1 268/4885NOS2 223/4885NOS3 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.